Dawn Millington

Suggest Changes
Learn More
OBJECTIVE To assess the efficacy/safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, compared with glimepiride over 104 weeks in patients with type 2 diabetes inadequately controlled(More)
  • 1